Alexion Pharmaceuticals is likely "on the radar" as a takeover candidate, but biotech company Amgen doesn't fit logically as an acquirer, an analyst said. Alexion stock dipped Friday.

source https://finance.yahoo.com/m/79e05f1c-f5f1-3670-a85b-afd1b2f5d804/why-alexion-makes-sense-as-a.html?.tsrc=rss